Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Longitude Capital Partners, Llc and Corcept Therapeutics Inc (NASDAQ:CORT)

Page 1 of 10

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Longitude Capital Partners 0 5,836,047 0 5,836,047 5,836,047 5.2%
Longitude Venture Partners 0 5,836,047 0 5,836,047 5,836,047 5.2%
Longitude Capital Associates 0 5,836,047 0 5,836,047 5,836,047 5.2%
Juliet Tammenoms Bakker 171,610 6,143,547 171,610 6,143,547 6,315,1572, 5.6%
Patrick G. Enright 272,281 6,143,547 272,281 6,143,547 6,415,8282, 5.7%
Date ofTransaction No. of Shares Sale Price PerShare of Common Stock(1)LVP

Page 1 of 10 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

CORCEPT THERAPEUTICS INCORPORATED

(Name of Issuer)

COMMON
STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

218352102

(CUSIP Number)

Patrick G. Enright

Managing Member

Longitude Capital Partners, LLC

800 El Camino Real, Suite 220

Menlo Park, CA 94025

(650) 854-5700

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

March 17, 2017

(Date of Event Which Requires Filing of
this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be
sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

(Continued on following pages)

(Page 1 of 10 Pages)

Follow Corcept Therapeutics Inc (NASDAQ:CORT)
Trade (NASDAQ:CORT) Now!
Page 1 of 10